Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Anika Therapeutics Inc. (ANIK) vs BioAge Labs, Inc. (BIOA)

Anika Therapeutics Inc. and BioAge Labs, Inc. are both Drug Manufacturers Specialty & Generic companies. BioAge Labs, Inc. is the larger, with a market value of $337.4M against $270.7M — 1.2× the size. Anika Therapeutics Inc. has the higher net margin (−3.14% vs −912.3%) and the higher return on invested capital (−3.24% vs −118.3%). Across the 16 metrics below, Anika Therapeutics Inc. leads on 10 and BioAge Labs, Inc. on 6.

Valuation

Metric ANIK BIOA Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 2.25 30.53 2.25
P/B 1.98 0.84 1.90
Price to free cash flow 483.15 n/m 16.54
EV/EBITDA 508.54 0.00 12.29
EV/Sales 2.16 (0.04) 2.56
Earnings yield (1.28%) (33.76%) (2.99%)
Free cash flow yield 0.21% (76.82%) 0.00%

Profitability

Metric ANIK BIOA Drug Manufacturers Specialty & Generic median
Gross margin 62.16% 100.00% 53.94%
Operating margin (4.24%) (1,026.28%) 0.00%
Net margin (3.14%) (912.25%) 0.00%
Free cash flow margin 0.47% (2,345.11%) 0.00%
Return on equity (2.66%) (28.21%) (0.40%)
Return on assets (2.04%) (26.27%) (3.32%)
Return on invested capital (3.24%) (118.25%) 0.00%

Growth

Metric ANIK BIOA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 5.33% — 10.01%
EPS growth (last fiscal year) 80.16% 66.21% —
Revenue growth, 5-year CAGR (2.86%) — 6.74%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ANIK BIOA Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.05
Current ratio 4.48 17.19 2.31
Net debt to EBITDA 10.80 3.01 0.85

Dividend

Metric ANIK BIOA Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 — 0.00

Size

Metric ANIK BIOA Drug Manufacturers Specialty & Generic median
Market cap 270.74m 337.35m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack